Pacira BioSciences, Inc.
Six ETFs sold Pacira BioSciences (PCRX) shares on Oct. 22, totaling $10.5 million in net outflows. This extends a five-session trend of ETF selling. The largest sellers were DFSV, DFAT, and DFAS. Pacira has a market cap of $1.5 billion and reported a 17.5% revenue increase over the past year. The stock trades at a P/E of 104.96 and has returned 40.73% year to date.
Doma Perpetual Capital Management sold all 2.78 million shares of Pacira BioSciences (PCRX) at $36.39 per share on Oct. 8, 2026, eliminating a 16.36% portfolio position. Pacira, a specialty pharmaceutical company, has a $1.45B market cap and trades at a PE ratio of 104.90. GuruFocus values it at $29.42, suggesting a 24% premium. The firm's exit may reflect valuation concerns, as Pacira's stock is deemed modestly overvalued with strong momentum but negative growth trends.
PharmaCorp Rx Inc. (PCRX) named Andrew Hodson as CFO, effective Oct 27, 2026. He succeeds Terri Tatchell, who will retire and consult for three months. The company cited the move as part of its roll-up strategy.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning PCRX (Pacira BioSciences, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent PCRX coverage spans financial news, mergers & acquisitions and market movers.
In the last 30 days, PCRX insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($218K). The most active reporter was RIKER LAUREN, Senior Vice President, Finance, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Sustained ETF net selling suggests near-term positioning pressure and weaker incremental demand for PCRX shares.
The fund's full exit may signal overvaluation and could weigh on PCRX price.
CFO appointment may signal upcoming M&A or financing activity, potentially supporting the stock.
Negative pressure as the target is being taken private at a premium.
Pacira is directly exposed to deal premium and closing timeline, making it a primary trading vehicle for spread and certainty.
AlphAI scores every news story that mentions PCRX with an AI model for sentiment and relevance, and aggregates insider trades from Pacira BioSciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Six ETFs sold Pacira BioSciences (PCRX) shares on Oct. 22, totaling $10.5 million in net outflows. This extends a five-session trend of ETF selling. The largest sellers were DFSV, DFAT, and DFAS. Pacira has a market cap of $1.5 billion and reported a 17.5% revenue increase over the past year. The stock trades at a P/E of 104.96 and has returned 40.73% year to date.
3 min readDoma Perpetual Capital Management sold all 2.78 million shares of Pacira BioSciences (PCRX) at $36.39 per share on Oct. 8, 2026, eliminating a 16.36% portfolio position. Pacira, a specialty pharmaceutical company, has a $1.45B market cap and trades at a PE ratio of 104.90. GuruFocus values it at $29.42, suggesting a 24% premium. The firm's exit may reflect valuation concerns, as Pacira's stock is deemed modestly overvalued with strong momentum but negative growth trends.
2 min readPharmaCorp Rx Inc. (PCRX) named Andrew Hodson as CFO, effective Oct 27, 2026. He succeeds Terri Tatchell, who will retire and consult for three months. The company cited the move as part of its roll-up strategy.
1 min readViatris (VTRS) agreed to buy Pacira BioSciences (PCRX) for $1.65B in cash, or $36.50 per share. Coca-Cola (KO) may sell Costa Coffee, acquired for $5.1B in 2018. Devon Energy (DVN) will sell Eagle Ford assets to Crescent Energy (CRGY) for $4.2B. All deals involve significant cash transactions.
2 min readService Properties Trust (SSVC) received a $2.0B acquisition offer from TKO LLC. Viatris (VTRS) agreed to buy Pacira BioSciences (PCRX) for $1.65B. Option Care Health (OPCH) surged 34% after a $5.8B acquisition deal with CD&R and McKesson (MCK). Energy Transfer (ET) will acquire Vaquero Midstream for $2.625B. Emera (EMA) and Canadian Utilities (CDUAF) agreed to a $10B merger. Cenovus Energy (CVE) will acquire Athabasca Oil (ATHOF) for ~$5.7B.
1 min readPacira BioSciences (NASDAQ: PCRX) SVP Lauren Riker sold 6,000 shares for $217,920 at $36.32 each, under a 10b5-1 plan. She also acquired 6,000 shares via options. PCRX stock rose 44% in a week and 57% in a year. The company reported Q2 revenue of $192.4M, up 6%. Viatris acquired Pacira Pharmaceuticals for $1.65B, leading to mixed analyst reactions.
2 min readTruist Securities downgraded Pacira BioSciences to Hold, setting a $36.50 price target, close to its recent $36.39 close. Analysts cite market concerns over generic competition for Exparel and uncertainty about margin improvements and PCRX-201. Recent price targets for Pacira range from $28 to $36.50.
1 min readAnalysts updated price targets for several companies. Needham raised CrowdStrike's (CRWD) target to $310, Baird increased Humana's (HUM) to $596, and others adjusted targets for Robinhood (HOOD), Webull (BULL), Align (ALGN), Pacira (PCRX), Sailpoint (SAIL), Unity (U), and Arcturus (ARCT). AT&T's (T) target was cut by Scotiabank.
2 min readHC Wainwright downgraded Pacira BioSciences to Neutral with a $36.50 price target, matching its recent share price. The downgrade follows Viatris' acquisition agreement at $36.50 per share, citing slower growth and competitive pressures.
1 min readPacira BioSciences (PCRX) surged 44% to $36.46 after Vitaris agreed to acquire it for $1.65B. Veradermics (MANE) rose 14% to $136.72, while HealthStream (HSTM) gained 2% to $32.42. Concentra (CON) and Haemonetics (HAE) also hit 52-week highs on strong financials.
2 min read
